[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591246":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":42,"locations":28,"responsibleParty":48,"collaborators":52,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":28,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":28,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":79,"whyStopped":28,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":28},{"fullName":5,"class":6},"The Third Affiliated hospital of Zhejiang Chinese Medical University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"sham EA +CBZ group","SHAM_COMPARATOR","A cohort of 63 patients with TN will undergo treatment with CBZ in conjunction with a sham EA intervention.",[13,14],"Drug: Carbarmazepine","Procedure: Sham Electroacupuncture",{"label":16,"type":17,"description":18,"interventionNames":19},"EA+placebo group","EXPERIMENTAL","A cohort of 63 patients diagnosed with TN will undergo treatment involving a combination of placebo and EA. The EA procedures will be administered by licensed acupuncturists who have received standardized training.",[20,21],"Drug: Carbarmazepine Placebo","Procedure: Electroacupuncture",[23,29,34,38],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Carbarmazepine","Following enrollment, the patient's carbamazepine dosage remained consistent with the pre-enrollment dosage. Orally administered for two consecutive weeks.",[9],null,{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":28},"PROCEDURE","Sham Electroacupuncture","In this group, superficial needling (0.5-1 mm depth) was performed at non-meridian points located 1 cm lateral to: (1) primary local acupoints ST2 (Sibai), ST7 (Xiaguan), and ST4 (Dicang) on the affected side; (2) branch-specific supplementary points GB1 (Tongziliao) for ophthalmic branch involvement, SI18 (Quanliao) for maxillary branch involvement, and ST6 (Jiache) for mandibular branch involvement; and (3) bilateral distal points LI4 (Hegu) and TE5 (Waiguan). Local acupoint pairs (ST7 adjacent + GB1 adjacent, ST7 adjacent + SI18 adjacent, or ST7 adjacent + ST6 adjacent) and distal pairs (LI4 adjacent + TE5 adjacent) were connected to an electroacupuncture device. The electroacupuncture device was kept in the off state and did not generate any therapeutic current. The needles were retained for 60 minutes.Acupuncture treatment was administered for 5 consecutive days as one course, with a 2-day break between courses. A total of 2 courses were conducted.",[9],{"type":24,"name":35,"description":36,"armGroupLabels":37,"otherNames":28},"Carbarmazepine Placebo","CBZ placebo is a tablet with identical packaging and appearance to CBZ but lacks therapeutic effects. Patients were transitioned to a CBZ placebo at an equivalent daily dose post-enrollment. Orally administered for two consecutive weeks.",[16],{"type":30,"name":39,"description":40,"armGroupLabels":41,"otherNames":28},"Electroacupuncture","The primary acupoints selected were the affected side's Sibai (ST2), Xiaguan (ST7), and Dicang (ST4). Based on the affected nerve branch, additional acupoints were chosen: for the ophthalmic branch, Tongziliao (GB1); for the maxillary branch, Quanliao (SI18); and for the mandibular branch, Jiache (ST6). Distal acupoints included bilateral Hegu (LI4) and Waiguan (SJ5). Electroacupuncture was applied based on the affected nerve branch. For the ophthalmic branch, the local acupoints selected were Xiaguan + Tongziliao; for the maxillary branch, Xiaguan + Quanliao; and for the mandibular branch, Xiaguan + Jiache. The distal acupoints selected were Hegu + Waiguan. A sparse-dense wave, 2\u002F100Hz, was used, with a treatment duration of 60 minutes. The intensity of the electrical current was adjusted according to the patient's tolerance. Acupuncture treatment is administered in 5 consecutive days as one course, with a 2-day break between courses. A total of 2 courses are conducted.",[16],[43],{"name":44,"role":45,"phone":46,"phoneExt":28,"email":47},"Nisang Chen","CONTACT","+8615990031347","237247256@qq.com",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"SPONSOR_INVESTIGATOR","Yuanyuan Wu","Associate Professor",[53,56],{"name":54,"class":55},"Pingyang County Traditional Chinese Medicine Hospital","UNKNOWN",{"name":57,"class":55},"Jiaxing Traditional Chinese Medicine Hospital","100591246","the-alternative-effects-of-electroacupuncture-in-the-treatment-of-trigeminal-neuralgia-100591246",false,"NCT06977932","The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia","The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia: Protocol for a Multicentre Randomised Controlled Trial","Diagnostic Criteria\n\nDiagnosis was based on the criteria for trigeminal neuralgia (TN) as defined in the third edition of the International Classification of Headache Disorders (ICHD-3) published by the International Headache Society (IHS) in 2018. The diagnostic criteria included:\n\n1. recurrent unilateral facial pain occurring in the distribution of one or more divisions of the trigeminal nerve, without radiation outside the trigeminal territory, and meeting criteria (2) and (3);\n2. pain presenting with all of the following characteristics:\n\n   ① paroxysmal attacks lasting from a few seconds to 2 minutes;\n\n   ② severe intensity;\n   * electric shock-like, stabbing, or sharp quality;\n3. pain triggered by innocuous stimuli within the affected trigeminal distribution;\n4. exclusion of other facial pain disorders classified in ICHD-3.\n\n   Inclusion Criteria\n\n   All of the following criteria had to be met for study enrollment:\n   * fulfillment of the TN diagnostic criteria as stated above;\n\n     * age between 18 and 80 years, inclusive, irrespective of sex;\n\n       * receiving a stable daily dose of carbamazepine (200-400 mg); ④ consciousness clear, with intact pain perception and discrimination, and able to communicate effectively; ⑤ voluntary participation with written informed consent provided by the patient or their legal guardian\u002Fauthorized representative.\n\n   Exclusion Criteria\n\n   Participants were excluded if they met any of the following:\n   * comorbid epilepsy, head injury, or other relevant neurological disorders;\n\n     * significant impairment of cardiac, hepatic, or renal function;\n\n       * cognitive dysfunction, aphasia, psychiatric conditions, or inability to cooperate with treatment;\n\n         * poorly controlled hypertension or hyperglycemia;\n\n           ⑤ recent diagnosis of severe anxiety or depression;\n\n           ⑥ pregnancy or lactation;\n\n           ⑦ presence of a cardiac pacemaker or other contraindications to electroacupuncture therapy;\n\n           ⑧ current participation in another clinical trial.","ALL","18 Years","80 Years",{"count":69,"type":70},126,"ESTIMATED","INTERVENTIONAL",[73],"NA","Trigeminal neuralgia (TN), characterized by its refractory nature and recurrence, frequently leads to anxiety, depression, and insomnia, thereby significantly diminishing patients' quality of life and potentially inducing self-harm. Carbamazepine (CBZ) is the first-line medication for TN, yet it presents adverse effects such as addiction and the absence of analgesic effects upon cessation. Acupuncture, particularly electroacupuncture（EA）, has demonstrated efficacy in TN treatment, although its therapeutic outcomes are influenced by various factors. Consequently, this study aims to evaluate the clinical efficacy of EA for TN and its potential as an alternative to CBZ treatment.",[76],"Trigeminal Neuralgia",[39,78],"Randomized Controlled Trial","NOT_YET_RECRUITING","2026-03-02",{"date":82,"type":83},"2026-03-05","ACTUAL",{"date":85,"type":70},"2026-03-01",{"date":87,"type":70},"2028-12-31",{"name":50,"class":6}]